Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

COMPLETED

Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases

Lead Sponsor:

The Canadian Blood and Marrow Transplant Group

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Chronic Myeloproliferative Disorders

Graft Versus Host Disease

Eligibility:

All Genders

16-65 years

Phase:

PHASE3

Brief Summary

RATIONALE: Giving chemotherapy before a donor peripheral stem cell transplant or bone marrow transplant using stem cells from a brother or sister that closely match the patient's stem cells, helps sto...

Detailed Description

OBJECTIVES: Primary * Compare the time to treatment failure in patients with hematologic malignancies or other diseases treated with filgrastim (G-CSF)-mobilized matched-sibling donor peripheral blo...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Diagnosis of one of the following hematologic malignancies:
  • Acute myeloid leukemia in first complete remission or second complete remission
  • Chronic myeloid leukemia in chronic or accelerated phase
  • Myelodysplasia, including any of the following:
  • Refractory anemia (RA)
  • RA with ringed sideroblasts
  • RA with excess blasts (RAEB) I
  • RAEB in transformation
  • Chronic myelomonocytic leukemia
  • Other hematologic malignancy for which sibling donor stem cell transplantation with a myeloablative conditioning regimen is appropriate, including any of the following:
  • Indolent non-Hodgkin's lymphoma (NHL)
  • Aggressive NHL
  • Chronic lymphocytic leukemia
  • Hodgkin's lymphoma
  • Myelofibrosis
  • Hematologic malignancy not otherwise specified
  • HLA-matched sibling donor available meeting all of the following criteria:
  • 6/6 HLA match
  • HLA typing performed by serologic or DNA methodology for A and B and by DNA methodology for DRB1 (intermediate resolution)
  • Not identical twin with patient
  • PATIENT CHARACTERISTICS:
  • ECOG performance status 0-2
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No cognitive, linguistic, or emotional difficulty that would preclude participation in the quality-of-life component of the study
  • Able to communicate in English or French
  • No HIV antibody positivity
  • PRIOR CONCURRENT THERAPY:
  • Not specified

Exclusion

    Key Trial Info

    Start Date :

    March 1 2007

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    Estimated Enrollment :

    230 Patients enrolled

    Trial Details

    Trial ID

    NCT00438958

    Start Date

    March 1 2007

    Last Update

    March 5 2014

    Active Locations (16)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 4 (16 locations)

    1

    Fred Hutchinson Cancer Research Center

    Seattle, Washington, United States, 98109-1024

    2

    Institute of Medical and Veterinary Science

    Adelaide, South Australia, Australia, 5000

    3

    Royal Melbourne Hospital

    Parkville, Victoria, Australia, 3050

    4

    Vancouver Hospital and Health Science Center

    Vancouver, British Columbia, Canada, V5Z 4E3